Corcept (NASDAQ: CORT) director sells 10,000 shares in planned trade

Posted by Teresa Graham on Oct 17th, 2026

What happened

Corcept Therapeutics Inc (NASDAQ: CORT) said director James N. Wilson sold 10,000 shares of common stock on 2026-10-15. The filing says the shares sold for $114.48 to $116.30 each, for a total value of about $1.15 million. It also says the trades were made under a Rule 10b5-1 plan, and the form was signed on 2026-10-16.

After the sale, Wilson held 1,054,543 shares. OptimistFi's calculation puts the 10,000 shares sold at about 0.9% of his pre-trade position. The filing also says the plan was adopted on March 12, 2026, so the trade followed a prearranged schedule.

Key numbers

Metric	Latest	Source
Shares sold	10,000 shares	SEC Form 4
Sale price range	$114.48 to $116.30 per share	SEC Form 4
Total sale value	about $1.15 million	SEC Form 4
Shares held after sale	1,054,543 shares	SEC Form 4
Pre-trade position sold	0.9%	Calculated from SEC Form 4

Why it matters

The filing changes the ownership picture more than the operating story. Wilson kept a large stake after the trade, and the sale was small compared with that holding. The price band was also narrow, from $114.48 to $116.30 per share.

For investors, that makes this a watch item on ownership rather than on operations. The Rule 10b5-1 plan, adopted on March 12, 2026, also means the sale may have been set in advance. That limits how much investors should read into it.

The filing gives a clear snapshot of Wilson's position. It does not change Corcept's business results or outlook on its own.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

What's next

Corcept's next quarterly report is the next dated check on the investment case. OptimistFi's case is that Corcept works if its high-margin cortisol-modulation franchise keeps expanding and internally funds relacorilant and other selective modulators before generic, payer, or clinical-trial setbacks narrow the opportunity. A stronger report would support that view by showing the business still funds development work.

A weaker report would do the opposite. On this filing alone, the planned sale leaves the case mixed. Ownership changed, but there is no business result attached. The filing is useful mainly as a read on Wilson's position, not as a verdict on Corcept.